When Pfizer Inc. and Biotech SE’s Kovid-19 vaccine production lines shut down, the Shanghai Fosun Pharmaceutical Group company was forced to move it through a complex and expensive system of deep-freez airports, refrigerated vehicles and vaccination points across China. Will have to wait to deliver. After they reach vaccination centers, shots should be thawed to -70 ° C and injected within five days, if they do not deteriorate.
Then the greening journey from the warehouse freezer to the roll-up sleeve should be resumed – a month later to deliver a second booster shot. The roadmap sketched by the company that licensed the vaccine for Greater China, offering Pfizer’s experimental vaccine, offers a glimpse of the enormous and daunting logistical challenges faced by those who took the “extraordinary” final stage trials “Showed early results. A possible end to the year-long epidemic is expected.
That euphemism is now being diluted by the realization that none of the currently used vaccines have ever been made with the messenger RNA technology deployed in Pfizer’s shot, which instructs the human body to produce proteins that later Develops protective antibodies in.
This means that countries will have to avoid scratching the deep-freeze production, storage and transportation networks needed for the vaccine to survive. There is a need for large-scale investment and coordination, but ensures that only rich countries are guaranteed access – and even then only their urban population.
Read more AIIMS chief said that it is difficult to keep Pfizer at a temperature of minus 70 degrees Celsius
Where things stand in the race for a Kovid-19 vaccine: QuickTech
“Its production is expensive, its component is volatile. It also requires cold-chain transport and short shelf life,” said Ding Sheng, director of the Beijing-based Global Health Drug Discovery Institute. Melinda Gates Foundation.
The cost of deploying Pfizer Shot will bolster existing fears that rich countries will already get the best vaccine, despite an effort backed by the World Health Organization to say Kovacs raised $ 18 billion to buy vaccines for poor countries Is aimed at.
It also now presents an alternative to the developing world: seems like a sure bet, or to pay for the expensive construction of subzero cold-chain infrastructure to wait for a slower, more traditional vaccine, which protein Let’s drink batches or dormant viral particles. In living cells, and can be delivered through existing health care networks.
“If there is a protein-based vaccine that can achieve the same effect as the mRNA vaccine and requires billions of people to be vaccinated every year, then I will go for protein-based shots in the long run,” Ding said.
Even for supplements already in place in many countries, including Japan, the US and the UK, Pfizer vaccines will be severely impeded until the truck breaks down, the power runs out, the necessary workers become ill and The ice melts.
To deliver shots safely in mainland China and Hong Kong, Fosun will partner with state-owned Sinopharma Group Company, a pharmaceutical distributor with well-established networks across the country. Kovid-19, one of Sinopharm’s subsidiaries, is also developing vaccines. Packed in cold storage trucks, those vials will be transported to vaccination sites, where they can be melted and stacked in the fridge for 2–8 ° C for a maximum of five days before spoiling. Vaccine expert Michael Kinch of Washington University in St. Louis said, “Too much vaccine is likely to worsen by requiring extremely cold temperatures.” According to the company’s chairman Wu Yifang, it is also worth Fosun worth millions of crores. Fosun is considering importing vaccines in bulk and filling them in vials at the local plant. This would require further investment in production and storage.
Read more How Pfizer Vaccine Can Be Cold Relax for Some Asian Countries
The Vaccine Cargo Cavalry symbolizes the readiness of the historic airlift
The resulting price may be too high for many developing countries, including neighboring India, which has struggled to prevent the world’s second largest Coronavius outbreak and currently has no agreement to purchase the Pfizer vaccine.
Many people working in the country’s public health and pharmaceutical industry have already raised concerns that India lacks the necessary capacity and capacity to deliver vaccines in its vast rural areas and now has a population of over 1.3 billion people at breakneck speed have hope.
New Delhi-based global mass coordinator, a global coordinator of the People’s Health Movement, T. Sundaraman said that most of these vaccines require minus 70 degrees, which we cannot do in India alone. , Academics and civil society groups working on public health.
“Our current cold chains are not able to withstand the need of some districts for measles vaccines, and this is only for children under 3,” he said. “This is a very insignificant number compared to those who would need the Kovid-19 vaccine.”
When asked at a briefing on Tuesday whether the Indian government would like to buy any Pfizer vaccine, Health Ministry Secretary Rajesh Bhushan said that New Delhi is in talks with all vaccine manufacturers. He said that India was in a position to expand and strengthen its existing cold-chain capacity, but refused to immediately release any procurement details. Pfizer already has orders from some developing countries such as Peru, Ecuador and Costa Rica. It is unclear how extensive those countries plan to deliver the shots, but their small orders of less than ten million doses suggest limited deployment. Following the release of their positive preliminary data, some governments have left to finalize orders and begin negotiations with Pfizer and BioNotech. The European Union on Tuesday confirmed more than 300 million dose orders, while the Philippines, Singapore and Brazil said they were in talks.
Read more Fauci says that if the FDA approved it, he would take the new Pfizer vaccine
Pankaj Patel, president of Indian drugmaker Cadila Healthcare Ltd, said rolling a vaccine in a short space of time without a subzero issue would be a major challenge. Its own experimental plasmid DNA was shot by Kovid-19.
This is particularly so in areas where people are not easily contactable or have to travel long distances to reach vaccination centers. Previous vaccination campaigns show that many never show up for a second shot, public health experts said. Rising barriers mean that some developing countries may pass on the Pfizer vaccine, despite early signs of its exceptional efficacy.
“If we wait for an extra year and we have something possible to do to reach more people in this country, is it a bad business?” Asked Gagandeep Kang, Professor of Microbiology at Vellore, India-based Christian Medical College and member of WHO’s Global Advisory Committee on Vaccine Safety.
“Based on the cost of the Pfizer vaccine, the logistics of an ultra-cold storage – I don’t think we’re ready and I think it’s something that we have to weigh the benefits and costs very carefully,” he said.
STAY TUNED WITH US FOR MORE INTERESTING CONTENT ONLY ON DESINEW.XYZ